Taro had weakest sales in 22 quarters with 16% YoY (and 8% QoQ) decline to US$148m in Q3FY20. Higher intensity of competitive pricing and lack of volume growth in derma portfolio were key reasons for strong erosion in sales. Gross profit was US$94m, declined by 20% YoY and 8% QoQ, while gross margin was 63.7% compared to 66.6% in Q3FY19 and 63.1% in Q2FY20. EBITDA declined by 24% YoY (and 14% QoQ) to $63.6mn, while EBITDA...